Skip to main content
. 2022 Jul 26;13:909123. doi: 10.3389/fphar.2022.909123

FIGURE 3.

FIGURE 3

The IC50 values of four targeted drugs in two clusters. (A) Axitinib. (B) Pazopanib. (C) Sorafenib. (D) Sunitinib.